About this trial
Postoperative pain after laparoscopic major upper abdominal surgery (e.g., gastric, hepatic, gallbladder, pancreatic surgery) is often severe, and inadequate analgesia may lead to increased opioid use, opioid dependence, and poor functional recovery. Current analgesic techniques such as neuraxial block have safety concerns (e.g., hypotension, neurological injury), while transversus abdominis plane (TAP) block is ineffective for blocking the lateral cutaneous branches of intercostal nerves in the upper abdomen. The External Oblique Intercostal Plane Block (EOIB) is a novel regional block technique that has shown promise in reducing postoperative opioids and pain in small-scale studies, but evidence for its use in major upper abdominal surgery is limited. This randomized controlled trial (RCT) aims to evaluate the analgesic efficacy and safety of bilateral EOIB combined with standard multimodal analgesia versus standard multimodal analgesia alone in patients undergoing elective laparoscopic major upper abdominal surgery. The primary outcome is the total postoperative opioid consumption (measured as Morphine Milligram Equivalents, MME) within 24 hours. Secondary and additional outcomes include pain scores (Verbal Rating Scale, VRS), recovery quality (QoR-15 scale), incidence of adverse events, and hospital stay.
Eligibility criteria
Qualifiers
Obtain written informed consent from participants or their legal representatives
Age between 18 and 85 years
American Society of Anesthesiologists (ASA) physical status classification I-III
Scheduled for elective laparoscopic major upper abdominal surgery (e.g., gastric, hepatic, gallbladder, pancreatic surgery)
Disqualifiers
Hepatic disease (liver enzyme levels ≥ 2× the upper limit of normal)
Renal disease (serum creatinine levels ≥ 2× the upper limit of normal)
Allergy to local anesthetics or known study-related drugs
Pregnancy or lactation
Trial design
Treatments tested in this trial
- External Oblique Intercostal Plane Block
- Standard multimodal analgesia
Treatment groups
Sponsors and collaborators
Jun Zhang
Lead sponsor
Fudan University
Sponsor institution